{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 1,
        "evidence": "Fifty patients with a biopsy-proven lung adenocarcinoma were enrolled."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients were systemically administered 0.1 mg/kg of a fluorescent folate receptor alpha (FR\u03b1)-targeted molecular contrast agent by intravenous infusion."
      },
      "Objective": {
        "score": 1,
        "evidence": "We propose that a targeted molecular contrast agent could bind lung adenocarcinomas and then identify these tumors by real-time optical imaging at the time of surgery."
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 1,
        "evidence": "46/50 (92%) lung adenocarcinomas were fluorescent."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 5,
    "max_score": 25
  },
  "model": "gpt-4o"
}